Suet Nee Chen1,2, Raffaella Lombardi1,3, Jennifer Karmouch1,4, Ju-Yun Tsai1,5, Grace Czernuszewicz1, Matthew R G Taylor2, Luisa Mestroni2, Cristian Coarfa6, Priyatansh Gurha1, Ali J Marian1. 1. From the Center for Cardiovascular Genetics, Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston (S.N.C., R.L., J.K., J.-Y.T., G.C., P.G., A.J.M.). 2. Section of Cardiology, University of Colorado-Anschutz Medical Campus, Denver (S.N.C., M.R.G.T., L.M.). 3. Division of Cardiology, Department of Advanced Biomedical Science, University of Naples Federico II, Italy (R.L.). 4. MD Anderson Cancer Center, Houston, TX (J.K.). 5. Thermo Fisher Scientific, Taiwan (J.-Y.T.). 6. Department of Cell Biology, Baylor College of Medicine, Houston, TX (C.C.).
Abstract
RATIONALE: Mutations in the LMNA gene, encoding LMNA (lamin A/C), are responsible for laminopathies. Dilated cardiomyopathy (DCM) is a major cause of mortality and morbidity in laminopathies. OBJECTIVE: To gain insights into the molecular pathogenesis of DCM in laminopathies. METHODS AND RESULTS: We generated a tet-off bigenic mice expressing either a WT (wild type) or a mutant LMNA (D300N) protein in cardiac myocytes. LMNAD300N mutation is associated with DCM in progeroid syndromes. Expression of LMNAD300N led to severe myocardial fibrosis, apoptosis, cardiac dysfunction, and premature death. Administration of doxycycline suppressed LMNAD300N expression and prevented the phenotype. Whole-heart RNA sequencing in 2-week-old WT and LMNAD300N mice led to identification of ≈6000 differentially expressed genes. Gene Set Enrichment and Hallmark Pathway analyses predicted activation of E2F (E2F transcription factor), DNA damage response, TP53 (tumor protein 53), NFκB (nuclear factor κB), and TGFβ (transforming growth factor-β) pathways, which were validated by Western blotting, quantitative polymerase chain reaction of selected targets, and immunofluorescence staining. Differentially expressed genes involved cell death, cell cycle regulation, inflammation, and epithelial-mesenchymal differentiation. RNA sequencing of human hearts with DCM associated with defined LMNA pathogenic variants corroborated activation of the DNA damage response/TP53 pathway in the heart. Increased expression of CDKN2A (cyclin-dependent kinase inhibitor 2A)-a downstream target of E2F pathway and an activator of TP53-provided a plausible mechanism for activation of the TP53 pathway. To determine pathogenic role of TP53 pathway in DCM, Tp53 gene was conditionally deleted in cardiac myocytes in mice expressing the LMNAD300N protein. Deletion of Tp53 partially rescued myocardial fibrosis, apoptosis, proliferation of nonmyocyte cells, left ventricular dilatation and dysfunction, and slightly improved survival. CONCLUSIONS: Cardiac myocyte-specific expression of LMNAD300N, associated with DCM, led to pathogenic activation of the E2F/DNA damage response/TP53 pathway in the heart and induction of myocardial fibrosis, apoptosis, cardiac dysfunction, and premature death. The findings denote the E2F/DNA damage response/TP53 axis as a responsible mechanism for DCM in laminopathies and as a potential intervention target.
RATIONALE: Mutations in the LMNA gene, encoding LMNA (lamin A/C), are responsible for laminopathies. Dilated cardiomyopathy (DCM) is a major cause of mortality and morbidity in laminopathies. OBJECTIVE: To gain insights into the molecular pathogenesis of DCM in laminopathies. METHODS AND RESULTS: We generated a tet-off bigenic mice expressing either a WT (wild type) or a mutant LMNA (D300N) protein in cardiac myocytes. LMNAD300N mutation is associated with DCM in progeroid syndromes. Expression of LMNAD300N led to severe myocardial fibrosis, apoptosis, cardiac dysfunction, and premature death. Administration of doxycycline suppressed LMNAD300N expression and prevented the phenotype. Whole-heart RNA sequencing in 2-week-old WT and LMNAD300Nmice led to identification of ≈6000 differentially expressed genes. Gene Set Enrichment and Hallmark Pathway analyses predicted activation of E2F (E2F transcription factor), DNA damage response, TP53 (tumor protein 53), NFκB (nuclear factor κB), and TGFβ (transforming growth factor-β) pathways, which were validated by Western blotting, quantitative polymerase chain reaction of selected targets, and immunofluorescence staining. Differentially expressed genes involved cell death, cell cycle regulation, inflammation, and epithelial-mesenchymal differentiation. RNA sequencing of human hearts with DCM associated with defined LMNA pathogenic variants corroborated activation of the DNA damage response/TP53 pathway in the heart. Increased expression of CDKN2A (cyclin-dependent kinase inhibitor 2A)-a downstream target of E2F pathway and an activator of TP53-provided a plausible mechanism for activation of the TP53 pathway. To determine pathogenic role of TP53 pathway in DCM, Tp53 gene was conditionally deleted in cardiac myocytes in mice expressing the LMNAD300N protein. Deletion of Tp53 partially rescued myocardial fibrosis, apoptosis, proliferation of nonmyocyte cells, left ventricular dilatation and dysfunction, and slightly improved survival. CONCLUSIONS: Cardiac myocyte-specific expression of LMNAD300N, associated with DCM, led to pathogenic activation of the E2F/DNA damage response/TP53 pathway in the heart and induction of myocardial fibrosis, apoptosis, cardiac dysfunction, and premature death. The findings denote the E2F/DNA damage response/TP53 axis as a responsible mechanism for DCM in laminopathies and as a potential intervention target.
Authors: Eduardo Garcia-Gras; Raffaella Lombardi; Michael J Giocondo; James T Willerson; Michael D Schneider; Dirar S Khoury; Ali J Marian Journal: J Clin Invest Date: 2006-07 Impact factor: 14.808
Authors: Jop H van Berlo; Willem G de Voogt; Anneke J van der Kooi; J Peter van Tintelen; Gisèle Bonne; Rabah Ben Yaou; Denis Duboc; Tom Rossenbacker; Hein Heidbüchel; Marianne de Visser; Harry J G M Crijns; Yigal M Pinto Journal: J Mol Med (Berl) Date: 2004-11-13 Impact factor: 4.599
Authors: Sirisha M Cheedipudi; Scot J Matkovich; Cristian Coarfa; Xin Hu; Matthew J Robertson; Mary Sweet; Matthew Taylor; Luisa Mestroni; Joseph Cleveland; James T Willerson; Priyatansh Gurha; Ali J Marian Journal: Circ Res Date: 2019-04-12 Impact factor: 17.367
Authors: Sirisha M Cheedipudi; Jinzhu Hu; Siyang Fan; Ping Yuan; Jennifer Karmouch; Grace Czernuszewicz; Matthew J Robertson; Cristian Coarfa; Kui Hong; Yan Yao; Hanna Campbell; Xander Wehrens; Priyatansh Gurha; Ali J Marian Journal: Cardiovasc Res Date: 2020-05-01 Impact factor: 10.787
Authors: Chia Yee Tan; Jing Xuan Wong; Pui Shi Chan; Hansen Tan; Dan Liao; Weiming Chen; Lek Wen Tan; Matthew Ackers-Johnson; Hiroko Wakimoto; Jonathan G Seidman; Christine E Seidman; Ida Gjervold Lunde; Feng Zhu; Qidong Hu; Jinsong Bian; Jiong-Wei Wang; Roger S Foo; Jianming Jiang Journal: Circ Res Date: 2019-09-09 Impact factor: 17.367
Authors: Mary E Haywood; Andrea Cocciolo; Kadijah F Porter; Evgenia Dobrinskikh; Dobromir Slavov; Sharon L Graw; T Brett Reece; Amrut V Ambardekar; Michael R Bristow; Luisa Mestroni; Matthew R G Taylor Journal: J Mol Cell Cardiol Date: 2020-01-18 Impact factor: 5.000
Authors: Julien L P Morival; Halida P Widyastuti; Cecilia H H Nguyen; Michael V Zaragoza; Timothy L Downing Journal: Clin Epigenetics Date: 2021-07-10 Impact factor: 7.259